Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects
Latest Information Update: 13 Dec 2023
At a glance
- Drugs TQH 2929 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 12 Dec 2023 New trial record